Skip to main content

Table 7 PICOT question 4: influence of ICS particle size on asthma outcomes: summary of results of matched database studies

From: Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group—European Academy of Allergy and Clinical Immunology Task Force

ReferenceOutcomesTreatmentsPopulationDatabaseResults
Van Aalderen et al. [67]ClinicalBDP pMDI
St versus EF
Initiation
Step-up
Vs LABA
Children 5–11UK (CPRD)
US (Optuminsight)
EF > St
EF = adding LABA
Price et al. [70]ClinicalBDP pMDI
St versus EF
Initiation
Switch
12–80UK GPRD CPRDEF > St
Price et al. [71]ClinicalpMDI
St FP versus EF BDP
Initiation
Step-up
5–60UK GPRDEF ≥ St at lower doses
Barnes et al. [40]ClinicalBDP pMDI
St versus EF
Initiation
Step-up
5–60UK GPRDEF > St
Martin et al. [68]C-EBDP/FP pMDI
St versus EF
Initiation
12–60/12–80UK/USEF dominant
Colice et al. [69]C-EpMDI
St FP versus EF BDP
Initiation
Step-up
12–80UK/USEF ≥ St at lower doses and costs
Price et al. [32]C-ESt FP-SAL versus EF BDP-FOR18–80UK GPRD CPRDEF ≥ St at lower doses
EF dominant
  1. EF extra-fine, St standard size, BDP beclomethasone dipropionate, SAL salmeterol; FOR, formoterol, FP fluticasone propionate, pMDI pressurized metered-dose inhaler